SOUTH PLAINFIELD, N.J., Feb. 17, 2011 /PRNewswire/ -- Dr. Abraham Abuchowski, CEO and Scientific Founder of Prolong Pharmaceuticals, was honored by the U.S. Small Business Administration on February 15 with their inaugural Tibbetts Award for leadership in innovation and job creation. Dr. Abuchowski was one of eight individuals recognized, and the only honoree in the pharmaceutical/biopharmaceutical industry.
Dr. Abuchowski was the originator of the PEGylation technology, now the most widely-used protein drug delivery system in the world. Prior to being one of the founders of Prolong Pharmaceuticals, Dr. Abuchowski founded Enzon Pharmaceuticals, now a fully integrated, publicly-traded company. During his time as CEO Enzon successfully introduced the PEGylation technology and brought three new protein-based drugs to market with FDA approval. PEGylated drugs have garnered sales in the tens of billions of dollars around the world.
The Tibbetts Award winners were honored for the critical role they play in research and development for the government and for their success in driving innovation and creating new jobs. "Winning the future requires redoubling our commitment to supporting innovative entrepreneurs like those we honor with Tibbetts Awards," said Karen Mills, SBA administrator. "Their stories illustrate the promise of the new generation of innovative entrepreneurs and remind us all how central the success of one high growth small business can be to our competitiveness as a nation."
About Prolong Pharmaceuticals
Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing biopharmaceutical products targeting the treatment of anemia resulting from an oxygen deficiency. First founded in 2002 as a research company, Prolong is focused on sickle cell anemia, diabetic ischemia, and several trauma indications. The company's senior management team includes inventors of the most successful drug del